Rizzo A.; Mollica V.; Santoni M.; Massari F., Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis, «EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY», 2021, 15, pp. 1225 - 1232 [articolo]
Basso U.; Procopio G.; Fornarini G.; Massari F.; Bearz A.; Fratino L.; Milella M.; Bassanelli M.; Ermacora P.; Bimbatti D.; Verzoni E.; Rizzo M.; Porta C., Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16), «ONCOLOGY», 2021, 99, pp. 747 - 755 [articolo]
Marchetti A.; Rosellini M.; Mollica V.; Rizzo A.; Tassinari E.; Nuvola G.; Cimadamore A.; Santoni M.; Fiorentino M.; Montironi R.; Massari F., The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory?, «INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES», 2021, 22, Article number: 6237, pp. 6237 - 6237 [articolo]Open Access
Rizzo A.; Mollica V.; Cimadamore A.; Santoni M.; Scarpelli M.; Schiavina R.; Cheng L.; Lopez-Beltran A.; Brunocilla E.; Montironi R.; Massari F., TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review, «TRANSLATIONAL ANDROLOGY AND UROLOGY», 2021, 10, pp. 1541 - 1552 [articolo]Open Access
Cimadamore A.; Cheng L.; Scarpelli M.; Massari F.; Mollica V.; Santoni M.; Lopez-Beltran A.; Montironi R.; Moch H., Towards a new WHO classification of renal cell tumor: What the clinician needs to know-a narrative review, «TRANSLATIONAL ANDROLOGY AND UROLOGY», 2021, 10, pp. 1506 - 1520 [articolo]Open Access
Rosellini M.; Santoni M.; Mollica V.; Rizzo A.; Cimadamore A.; Scarpelli M.; Storti N.; Battelli N.; Montironi R.; Massari F., Treating prostate cancer by antibody-drug conjugates, «INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES», 2021, 22, Article number: 1551, pp. 1 - 15 [articolo]Open Access
Mollica V.; Brocchi S.; Dall'olio F.G.; Marcolin L.; Paccapelo A.; Santoni M.; Rizzo A.; Montironi R.; Golfieri R.; Massari F.; Ardizzoni A., Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mrcc: When recist is not enough, «CANCERS», 2021, 13, Article number: 3492, pp. 1 - 10 [articolo]Open Access
Mollica V.; Di Nunno V.; Santoni M.; Cimadamore A.; Scarpelli M.; Lopez-Beltran A.; Cheng L.; Mariani C.; Battelli N.; Montironi R.; Massari F., An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer, «EXPERT REVIEW OF MOLECULAR DIAGNOSTICS», 2020, 20, pp. 207 - 217 [articolo]
Aurilio G.; Cimadamore A.; Mazzucchelli R.; Lopez-Beltran A.; Verri E.; Scarpelli M.; Massari F.; Cheng L.; Santoni M.; Montironi R., Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications, «CELLS», 2020, 9, Article number: 2653, pp. 1 - 14 [articolo]Open Access
Vitale G.; Lamberti G.; Comito F.; Di Nunno V.; Massari F.; Morelli M.C.; Ardizzoni A.; Gelsomino F., Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience, «EXPERT OPINION ON BIOLOGICAL THERAPY», 2020, 20, pp. 1047 - 1059 [articolo]
Mollica V.; Rizzo A.; Massari F., Avelumab maintenance for urothelial carcinoma, «THE NEW ENGLAND JOURNAL OF MEDICINE», 2020, 383, pp. 2482 - 2483 [articolo]
Di Nunno V.; Mollica V.; Massari F.; De Wit R.; De Bono J.; Castellano D., Cabazitaxel in metastatic prostate cancer, «THE NEW ENGLAND JOURNAL OF MEDICINE», 2020, 382, pp. 1286 - 1286 [articolo]
Iacovelli R.; Ciccarese C.; Facchini G.; Milella M.; Urbano F.; Basso U.; De Giorgi U.; Sabbatini R.; Santini D.; Berardi R.; Santoni M.; Bracarda S.; Massari F.; Masini C.; De Tursi M.; Ricotta R.; Buti S.; Zustovich F.; Sepe P.; Rossetti S.; Maruzzo M.; Cortesi E.; Tortora G.; Procopio G., Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis, «TARGETED ONCOLOGY», 2020, 15, pp. 495 - 501 [articolo]
Mollica V.; Maggio I.; Lopez-Beltran A.; Montironi R.; Cimadamore A.; Cheng L.; Rizzo A.; Giunchi F.; Schiavina R.; Fiorentino M.; Brunocilla E.; Massari F., Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors, «EXPERT REVIEW OF ANTICANCER THERAPY», 2020, 20, pp. 755 - 763 [articolo]
Iacovelli R.; Ciccarese C.; Facchini G.; Milella M.; Urbano F.; Basso U.; De Giorgi U.; Sabbatini R.; Santini D.; Berardi R.; Santoni M.; Bracarda S.; Massari F.; Masini C.; De Tursi M.; Ricotta R.; Buti S.; Zustovich F.; Sepe P.; Rossetti S.; Maruzzo M.; Cortesi E.; Tortora G.; Procopio G., Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis (Targeted Oncology, (2020), 15, 4, (495-501), 10.1007/s11523-020-00732-y), «TARGETED ONCOLOGY», 2020, 15, pp. 691 - 691 [articolo]
